Search results
Results From The WOW.Com Content Network
Bortezomib, sold under the brand name Velcade among others, is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma. [4] This includes multiple myeloma in those who have and have not previously received treatment. [ 3 ]
Proteasomes are large proteins complexes that are used to break down other proteins. These inhibitors are being studied for the treatment of cancer. Drugs such as bortezomib, carfilzomib, and ixazomib are already approved for use in treating multiple myeloma and mantle cell lymphoma. They also work as immunosuppressants and inhibit bone resorption.
Bortezomib/dexamethasone is a combination drug against multiple myeloma. [1] When bortezomib is used by the trade name Velcade, the combination is called Vel/Dex (or Vel-Dex or Veldex ). Bortezomib is a proteasome inhibitor and dexamethasone is a corticosteroid .
Azacitidine is a chemical analogue of the nucleoside cytidine, which is present in DNA and RNA.It is thought to have antineoplastic activity via two mechanisms – at low doses, by inhibiting of DNA methyltransferase, causing hypomethylation of DNA, [16] and at high doses, by its direct cytotoxicity to abnormal hematopoietic cells in the bone marrow through its incorporation into DNA and RNA ...
Chemical drain cleaners are available through hardware stores, although some may be intended for use by licensed plumbers. They may contain either strong acids (in liquid forms) or strong alkalis (in either solid or liquid forms). These cleaners contain chemicals that dissolve at least some of the material causing the clog.
Clonazepam ODT blister pack and tablet Etizest-1 MD (Etizest-brand 1mg-doskk etizolam mouth-dissolving (MD) blister pack and opened tablet. An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications.
Oprozomib [1] (codenamed ONX 0912 and PR-047) is an orally active second-generation proteasome inhibitor developed by Proteolix, which was acquired by Onyx Pharmaceuticals, an Amgen subsidiary, in 2009.
Lisocabtagene maraleucel, sold under the brand name Breyanzi, is a cell-based gene therapy used to treat B-cell lymphomas, including follicular lymphoma. [3] [6]Side effects include hypersensitivity reactions, serious infections, low blood cell counts, and a weakened immune system. [6]